Article
Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.
Gut - 1 Nov 2018
Llibre Alba, Shimakawa Yusuke, Mottez Estelle, Ainsworth Shaun, Buivan Tan-Phuc, Firth Rick, Harrison Elliott, Rosenberg Arielle R, Meritet Jean-François, Fontanet Arnaud, Castan Pablo, Madejón Antonio, Laverick Mark, Glass Allison, Viana Raquel, Pol Stanislas, McClure C Patrick, Irving William Lucien, Miele Gino, Albert Matthew L, Duffy Darragh
Abstract excerpt
OBJECTIVE: Recently approved direct acting antivirals provide transformative therapies for chronic hepatitis C virus (HCV) infection. The major clinical challenge remains to identify the undiagnosed patients worldwide, many of whom live in low-income and middle-income countries, where access to nucleic acid testing remains limited. The aim of this study was to develop and validate a point-of-care (PoC) assay for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
